Clonal hematopoiesis of indeterminate potential and risk of hepatocellular carcinoma: New kids on the block
- PMID: 38640021
- PMCID: PMC12068683
- DOI: 10.1097/HEP.0000000000000898
Clonal hematopoiesis of indeterminate potential and risk of hepatocellular carcinoma: New kids on the block
Conflict of interest statement
Conflicts of interest:
Hsian-Rong Tseng is employed by and owns stock in Eximus Diagnostics. He owns stock in CytoLumina and Pulsar. Ju Dong Yang consults for AstraZeneca, Eisai, Exact, Excelixis, Fujifilm, Gilead, and Merck. The remaining author has no conflicts to report.
Comment on
-
Impact of clonal hematopoiesis of indeterminate potential on hepatocellular carcinoma in individuals with steatotic liver disease.Hepatology. 2024 Oct 1;80(4):816-827. doi: 10.1097/HEP.0000000000000839. Epub 2024 Mar 11. Hepatology. 2024. PMID: 38470216 Free PMC article.
References
-
- Lee YT, Wang JJ, Luu M, Tseng HR, Rich NE, Lu SC, Nissen NN, et al. State-Level HCC Incidence and Association With Obesity and Physical Activity in the United States. Hepatology 2021;74:1384–1394. - PubMed
-
- Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73–84. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical